Divi's Lab.
Divis Laboratories Q4 FY26: Capex ₹1,400 Cr
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #52 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Divi's Lab. Q4 FY26 key numbers
- Revenue
- Despite raw material cost pressures and freight increases, currency depreciation (INR vs USD/Euro) is expected to provide a partial offset, benefiting overall revenue.
As stated in Divi's Lab.'s Q4 FY26 earnings call transcript · published 31 May 2026. Reported figures, not investment advice.
The short version
The company projects a double-digit revenue growth going forward. Divi's Laboratories expects double-digit revenue growth going forward, as stated by Nilima Prasad Divi.
From Divi's Lab.'s Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- The company projects a double-digit revenue growth going forward.
- Growth will be driven by both volume pickup in existing generic products and the addition of new molecules as products come off patent in 2026-27.
- The custom synthesis (CS) business is expected to contribute increasingly, though timelines for revenue realization from long-term supply agreements can vary from 6 months to 3 years.
- Despite raw material cost pressures and freight increases, currency depreciation (INR vs USD/Euro) is expected to provide a partial offset, benefiting overall revenue.
- The company emphasizes a continuous product pipeline in both generics and custom synthesis, supporting steady volume growth.
2 more points from Divi's Lab.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Divi's Lab. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital work in progress as of March 31, 2026 stood at ₹2,113 crores.
- Significant ongoing expansions, including a ₹1,500 crore expansion at Kakinada with ₹600 crores already capitalized.
- Capex for fiscal year 2026-27 expected to remain steady unless new custom synthesis or other projects arise.
- Historical capex was ₹1,400 crores last year; ₹2,500 crores capex done this year (about 24% of sales), significantly higher than the historical average of 13% of sales.
- Capex projects include building GMP capacities in Unit 1 and Unit 2, and expansion for pre-chemistry raw materials at Unit 3, Kakinada.
- Capex conversion to revenue typically takes around 2 years, subject to customer regulatory approvals and timelines.
2 more points from Divi's Lab.'s call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Divi's Lab. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is engaged in multiple custom synthesis (CS) projects, some in validation, and others in prequalification or R&D stages, indicating a healthy project pipeline.
- Ramp-up of dedicated capacities depends on customer regulatory approvals; commercial production starts upon customer volume confirmation.
- The company maintains an active supply chain and customer engagement to manage ongoing and incoming demand efficiently.
Divi's Lab. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.8K Cr, net profit ₹751 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Divi's Lab.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Divi's Lab. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Divi's Lab. Q4 FY26 results?
The company projects a double-digit revenue growth going forward. Divi's Laboratories expects double-digit revenue growth going forward, as stated by Nilima Prasad Divi.
What is Divi's Lab. share price analysis?
Divi's Lab. currently shows a neutral. The stock trades at a P/E of 83.5 with a market cap of ₹248,877 Cr. Investors should review the full earnings analysis for detailed insights.
Is Divi's Lab. planning capital expenditure?
Capital work in progress as of March 31, 2026 stood at ₹2,113 crores.
Keep Divi's Lab. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.